Biohaven Pharmaceutical

Forecast & Rating17 analysts currently cover Biohaven Pharmaceutical, with about 76.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $23.07, about 68.1% upside from the current price of $13.72. Price targets range from $10.00 to $50.00 — a wide spread, showing clear disagreement over just how much Biohaven Pharmaceutical can rise. Historically, about 62.6% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Biohaven Pharmaceutical closely still see room for the stock to rise. Data as of Aug 18, 2026; for reference only and not investment advice.